Prgf Treatment In Sequelae Of Adenovirus Conjunctivitis
Published 2022 - 40th Congress of the ESCRS
Reference: FPS06.06 | Type: Free paper | DOI: 10.82333/tvx0-jk34
Authors: Edmar Uribe* 1 , Jesus Merayo 2 , Ronald Sanchez 2
1Corneal and external disease - Uveitis,Clinica Delgado,Lima,Peru;Universidad San Martin de Porres,Lima,Peru;Corneal and External disease - Uveitis,Instituto Unversitario Fernandez Vega - Universidad de Oviedo,Oviedo,Spain, 2Ocular Inmunology and Uveitis,Instituto Unversitario Fernandez Vega - Universidad de Oviedo,Oviedo,Spain
Purpose
To provide data about efficacy and safety of Plasma Rich in Growth Factors (PRGF) eye drops in sequelae of adenovirus conjunctivitis (SAC), and to analyze the possible influence of certain variables on treatment outcomes.
Setting
Methods
This retrospective study included patients of IUFV (Fernández-Vega University Institute) Eye Surface Unit between 2012 and 2013, without response to standard therapy (artificial tears, corticosteroids, cyclosporine, autologous serum) and presence of SEI (sub-epithelial infiltrates). The treatment given was PRGF eye drops 4 times/ day ± standard therapy. Primary endpoint was the resolution time of SEI. The Best Corrected Visual Acuity (BCVA) and intraocular pressure (IOP) were also evaluated. Safety assessment was also performed.
Results
Twenty-eight eyes (14 patients) were evaluated, mean age was 46.5 ± 19.3 (21-79) years, previous time with SEI was 10.1 ± 13.8 (0.5-36) months. The patients needs 2.07 ± 0.6 (1-3) PRGF cycles (1 cycle = 6 weeks) to achieve corneal transparency. Ninety percent of patients continued with their standard therapy plus PRGF eye drops. Twenty four patients (86%) resolved SEI, follow up time was 19.1 ± 12.8 (2.3-40.5) months. The BCVA improve 24.4% (p< 0.01), and no statistical change in IOP. No adverse events were reported.
Conclusions
Conclusions
PRGF eye-drops could be a effective therapeutic option for patients with SEI because sequelae of adenovirus, improving BCVA and safe in its use.